Table 1

Demographic and clinical features of 112 patients by 2010 ACR/EULAR RA criteria classification

2010 ACR/EULAR RA criteria
Classified as RANot classified as RAp Value
N6646
Age (years)49.5 (15.5)46.3 (14.1)0.318
Gender (N (%))0.492
 Female53 (80.3%)34 (73.9%)
 Male13 (19.7%)12 (26.1%)
Disease duration (years)6.0 (6.0)4.3 (6.5)0.007
Follow-up (months)6.1 (2.7)6.6 (2.4)0.347
New patient (N (%))11 (16.7%)17 (37.0%)0.025
Physician diagnosis (N (%))<0.001
 (RA)29 (43.9%)1 (2.2%)
 Systemic lupus erythematosus16 (24.2%)8 (17.4%)
 Psoriatic arthritis9 (13.6%)15 (32.6%)
 Osteoarthritis6 (9.1%)6 (13.0%)
 Other6 (9.1%)16 (34.8%)
Medication usage (N (%))
 NSAID17 (25.8%)11 (23.9%)0.999
 Steroid35 (53.0%)16 (34.8%)0.082
 DMARD55 (83.3%)27 (58.7%)0.005
 Biological30 (45.5%)11 (23.9%)0.028
 Cytotoxic4 (6.1%)2 (4.4%)0.999
Rheumatoid factor (RF) (N (%))<0.001
 Positive30 (45.6%)3 (6.5%)
 Negative36 (54.4%)43 (93.5%)
RF/ACPA (N (%))<0.001
 Negative29 (47.5%)38 (90.5%)
 Low titre7 (11.5%)4 (9.5%)
 High titre25 (41.0%)0 (0.0%)
CRP/ESR (N (%))0.014
 Positive51 (77.3%)25 (54.3%)
 Negative15 (22.7%)21 (45.7%)
Joint count (N (%))<0.001
 1–3 Small joints2 (3.0%)10 (21.7%)
 4–10 Small joints10 (15.2%)16 (34.9%)
 10+ Small joints54 (81.8%)0 (0.0%)
 1 Large joint0 (0.0%)10 (21.7%)
 2–10 Large joints0 (0.0%)10 (21.7%)
  • CRP, C reactive protein; DMARD, disease modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis.